Search Results 101-110 of 17270 for Irinotecan
Patients must have received at least 2 regimens containing 5-Fluorouracil,oxaliplatin, or irinotecan. Patients to be enrolled in the Cetuximab or ...
Previous completion of at least three (3) months of EITHER gemcitabine plus nab-paclitaxel OR FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan and leucovorin) ...
Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine ...
irinotecan,; trastuzumab in case of HER2-positive; ramucirumab. Disease progression within 6 months after the last treatment. Adequate bone-marrow, renal and ...
... irinotecan; Development of the first population pharmacokinetic model for the anti-inflammatory drug sulindac; Characterization of the pharmacokinetics and ...
1.1) following completion of 4 cycles of first-line platinum-based therapy (cisplatin or carboplatin in combination with etoposide or irinotecan). Subjects ...
Known hypersensitivity to irinotecan or its excipients. Known history of allergies or sensitivities to gentamicin. History of or current evidence of any ...
Participation eligibility · standard approved therapies: fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; · an anti-VEGF biological therapy (eg ...
... irinotecan. Availability of FFPE tumor specimen for neoantigen assessment. Measurable disease according to RECIST v1.1. Lesions amenable to biopsy. ≥ 12 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.